SF1126
- Generic Name
- SF1126
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- DL0Q912033
- Background
SF1126 is an integrin-targeted PI3 kinase inhibitor.
- Indication
For the treatment of various forms of cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- SignalRX Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03059147
- Locations
- ๐บ๐ธ
UC San Diego Moores Cancer Center, La Jolla, California, United States
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Ezra Cohen
- Target Recruit Count
- 1
- Registration Number
- NCT02644122
- Locations
- ๐บ๐ธ
UC San Diego Moores Cancer Center, La Jolla, California, United States
SF1126 for Patients With Relapsed or Refractory Neuroblastoma
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2018-08-20
- Target Recruit Count
- 4
- Registration Number
- NCT02337309
- Locations
- ๐บ๐ธ
Childrens Hospital Boston, Dana-Farber Cancer Institute., Boston, Massachusetts, United States
๐บ๐ธUniversity of Chicago Comer Children's Hospital, Chicago, Illinois, United States
๐บ๐ธAFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Semafore Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00907205
- Locations
- ๐บ๐ธ
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธScottsdale Clinical Research Institute, Scottsdale, Arizona, United States
๐บ๐ธArizona Cancer Center, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.